Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301


16.09.2021 - 20:00 | Weng Fine Art AG
16.09.2021 - 15:45 | Reederei Herbert Ekkenga Aktiengesellschaft Passagierschiffahrt
16.09.2021 - 14:00 | KFM Deutsche Mittelstand AG
Business news for the stock market

Medigene AG: Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019

Martinsried/Munich (pta006/17.05.2019/07:30) - Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene's DC vaccine during the annual congress of the European Hematology Association (EHA) taking place from 13 - 16 June in Amsterdam.

Medigene will present a poster on June 15 from 17:30-19:00 entitled "Interim Analysis of a WT-1 and PRAME ` Fast-DC´ vaccine shows safety as active immunotherapy for the prevention of AML relapse".

For the full abstract of the poster, please follow this link:

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.

emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg
contact person: Medigene PR/IR
phone: +49 89 2000 33 3301
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
98.321 Abonnenten
193.042 Meldungen
79.510 Pressefotos


16.09.2021 - 17:00 | brix IT Solutions GmbH
16.09.2021 - 10:00 | pressetext.redaktion
16.09.2021 - 08:55 | Die Unternehmersoftware est. 1999 GmbH
16.09.2021 - 06:10 | pressetext.redaktion
15.09.2021 - 13:30 | pressetext.redaktion